Translational research is a high-risk, iterative phase of the drug development pipeline that is critical in ensuring both a drug’s safety and efficacy. Key questions are answered about a potential drug in translational research: How quickly is it absorbed? How is it distributed to different tissues? How is it metabolized and excreted? At what dose is the drug toxic – and does it produce a beneficial effect in animal models of the disease?
Here, we feature two translational research projects that CDRD is working on in collaboration with academic investigators, and with funding from The MS Society of Canada – the ultimate goal being the development of disease-modifying therapies for people living with progressive MS.
